ECTRIMS 2023

More than three-quarters of people with relapsing forms of multiple sclerosis (MS) who received Zeposia (ozanimod) in the RADIANCE clinical trial and its extension study still haven’t experienced confirmed disability progression after…

New research by scientists in Austria may shed light on the link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS), and explain why only some people infected with EBV — previously found to…

The risk of converting to secondary-progressive multiple sclerosis (SPMS) has declined in recent years for patients who have an earlier disease onset, an analysis of data from the Swedish MS Registry indicates. The…

Multiple sclerosis (MS) patients had significantly more sickness-related work absences in the years leading up to their disease onset than people in the general population, a recent Swedish analysis showed. Scientists believe the…

Blood levels of neurofilament light chain (NfL), a marker of nerve damage, were seen to increase about a year or two prior to disability worsening in people with multiple sclerosis (MS), particularly among…

Use of high-efficacy therapies can lower the risk of disability progression in people with childhood-onset multiple sclerosis (MS), particularly if given in early disease stages when disabling symptoms are negligible. That’s according to…

Treatment with the investigational therapy fenebrutinib significantly reduced the number of new inflammatory lesions visible on MRI scans in people with relapsing forms of multiple sclerosis (MS). Pharmacological data from the study…

Treatment with tolebrutinib for up to nearly three years was tied to low relapse rates, stable disability, and few new brain lesions among people with relapsing forms of multiple sclerosis (MS), according…

Obese people with multiple sclerosis (MS) had faster disability accumulation, greater cognitive declines, and worse quality of life in the 15 years after diagnosis relative to patients with normal weight, according to an…